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Abstract
Background: Early inner ear development requires the strict regulation of cell proliferation, survival, migration and
differentiation, coordinated by the concerted action of extrinsic and intrinsic factors. Deregulation of these processes is
associated with embryonic malformations and deafness. We have shown that insulin-like growth factor I (IGF-I) plays a key
role in embryonic and postnatal otic development by triggering the activation of intracellular lipid and protein kinases. RAF
kinases are serine/threonine kinases that regulate the highly conserved RAS-RAF-MEK-ERK signaling cascade involved in
transducing the signals from extracellular growth factors to the nucleus. However, the regulation of RAF kinase activity by
growth factors during development is complex and still not fully understood.
Methodology/Principal Findings: By using a combination of qRT-PCR, Western blotting, immunohistochemistry and in situ
hybridization, we show that C-RAF and B-RAF are expressed during the early development of the chicken inner ear in
specific spatiotemporal patterns. Moreover, later in development B-RAF expression is associated to hair cells in the sensory
patches. Experiments in ex vivo cultures of otic vesicle explants demonstrate that the influence of IGF-I on proliferation but
not survival depends on RAF kinase activating the MEK-ERK phosphorylation cascade. With the specific RAF inhibitor
Sorafenib, we show that blocking RAF activity in organotypic cultures increases apoptosis and diminishes the rate of cell
proliferation in the otic epithelia, as well as severely impairing neurogenesis of the acoustic-vestibular ganglion (AVG) and
neuron maturation.
Conclusions/Significance: We conclude that RAF kinase activity is essential to establish the balance between cell
proliferation and death in neuroepithelial otic precursors, and for otic neuron differentiation and axonal growth at the AVG.
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Introduction
The vertebrate inner ear is responsible for the detection of
sound and balance, and it contains two main functional parts, the
auditory system dedicated to hearing and the vestibular system
that controls balance. This complex sensory organ derives from an
ectodermic region adjacent to the hindbrain, the otic placode. As
development proceeds, the otic placode thickens, invaginates and
forms the otic cup, which will then close to form an ectoderm-
detached, pear-shaped structure: the otic vesicle or otocyst [1].
The otic vesicle is an autonomous structure that contains the
genetic information required to generate most of the cell types and
structures of the adult inner ear, including the neurons of the
acoustic-vestibular ganglion (AVG) [2,3]. The AVG contains the
neural precursors of the auditory and vestibular ganglia, which
form a single ganglion at this stage of development. The neurons
involved are specified in the otic epithelium and these neuroblasts
migrate from the neurogenic zone to a nearby area where, after an
intense period of proliferation, they differentiate into post-mitotic
neurons that extend their processes to the sensory epithelium in
the brainstem nuclei through the VIIIth cranial nerve [1,2,4,5].
Otocysts can be explanted from the embryo and their ex vivo
development can be followed in a defined culture medium to study
the molecular cues that instruct the cellular diversity found in vivo
[4]. Through the combination of in vivo and organotypic culture
studies, it has been shown that Wnt, fibroblast growth factors,
neurotrophins and factors of the insulin family can reinitiate cell
proliferation of quiescent otic vesicles, to drive morphogenesis,
determine cell fate specification, and promote migration or final
differentiation [6–9].
Insulin-like growth factor I (IGF-I) has been shown to modulate
otic development in evolutionary distant species [4] and indeed,
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cochlear malformation in man and mice (MIM 147440) [10,11].
IGF-I deficit in the mouse is associated with caspase-3-mediated
apoptosis of immature cochlear neurons [12] and with altered
signaling pathways, including poor activation of Akt and ERK1/2,
and the up-regulation of p38 kinase pathways [13]. Cochlear
ganglion neurons have many immature traits including the
aberrant expression of the MEF2A, MEF2D, SIX 6 and MASH1
transcription factors [13]. In the chicken inner ear, IGF-I drives
cellular programs that are important for specific events during otic
development, including proliferation, survival, metabolism and
differentiation [7]. Both IGF-I and its high affinity IGF1R
receptor are expressed during inner ear development [6].
Moreover, endogenous otic IGF-I activity is essential for the
survival and neurogenesis of otic precursors due to its activation of
the PI3K/Akt kinase pathway [6,14]. On the other hand,
exogenous IGF-I mimics morphogenetic traits in vivo, promoting
neurogenesis and axon sprouting, accelerating the rate of cell
proliferation and improving cell survival by inhibiting apoptosis of
both epithelial and neural progenitors [6]. IGF-I can activate the
RAF-MEK-ERK cascade in the otic epithelium, and C-RAF is
essential for otic vesicle proliferation and morphogenesis [15].
However, it is not still fully clear how the strict balance between
signaling pathways is regulated by IGF-I during development.
RAF kinases are serine/threonine kinases whose activity is
modulated by growth factors and that play a central role in normal
and pathologic cellular processes, including development, cell
regeneration, cell senescence and cancer [16]. The first RAF
kinase identified was the oncogenic product of mouse sarcoma
virus 3611 [17] and since, the mammalian RAF kinases have been
shown to belong to a family that is formed by A-, B- and C-RAF.
In invertebrates only a single RAF kinase exists whereas the two
isoforms in birds are homologues of B- and C-RAF [18]. In
mammals, A-RAF is the less abundant kinase and it is expressed in
the urogenital and gastrointestinal systems. By contrast, B-RAF is
more abundant and it is found in the nervous system and gonads,
whereas C-RAF is ubiquitously expressed [19]. The study of
knock-out mice lacking each of these kinases has revealed that they
fulfill common and distinct functions [18,20], as well as shedding
light on how they are regulated, their distinct intracellular
localization [21] and association with scaffold proteins [22].
Indeed, B-RAF knock-out mice have defects in neural cell
lineages, including reduced cell proliferation in the neocortex,
and impaired migration and dendrite formation associated with
cortical neurons [20].
RAF kinases transmit growth factor signals from the receptor/
RAS complex via the phosphorylation of MEK in the cytosol. This
leads to the phosphorylation and activation of ERK that in turn,
can phosphorylate cytoplasmic and nuclear transcription factors
that regulate gene expression and cellular responses. Bcl-2 family
members are targets of the RAF-MEK-ERK pathway [23], and
therefore, RAF kinases are considered to be anti-apoptotic factors.
The activation of the RAS-RAF-MEK-ERK cascade is essential
for cellular proliferation during malignant transformation [16],
which has led to the synthesis of bi-aryl urea Sorafenib that inhibits
the catalytic activity of B-RAF and C-RAF and that also blocks
proangiogenic-receptor-tyrosine kinases [24]. B-RAF is the most
potent of the kinases that phosphorylates ERK [25] and it is
strongly expressed in the nervous system [26,27]. However, its
expression during inner ear development and the participation of
RAF kinases in AVG neurogenesis has not yet been explored.
Here we show that both B-RAF and C-RAF are present in the
inner ear during its early development in vivo, and that B-RAF
expression becomes restricted as development proceeds. IGF-I can
activate the RAF-MEK-ERK cascade in explanted otic vesicles
and by blocking RAF kinases with Sorafenib, we show that RAF
activity is essential for cell proliferation. By contrast, survival may
be recovered by IGF-I induction of the PI3K/Akt kinase pathway.
Finally, our data show that the RAF-MEK-ERK cascade is an
important mediator of otic neuronal survival, migration and the
outgrowth of neuronal processes.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined in the European Council Directive (86/609/
EEC), and all animal work was approved by the Ethics Committee
of the UAM and the Bioethics Committee of the Consejo Superior de
Investigaciones Cientificas.
Chicken embryos
Chicken embryos were obtained from fertilized eggs from a
local farm (Granja Santa Isabel, Cordoba, Spain) and they were
incubated in a humidified atmosphere at 37.8uC. Embryos were
staged as HH18, HH20, HH22, HH24, HH27 and HH34
according to Hamburger and Hamilton’s criteria [28].
Isolation, organotypic culture and treatment of otic
vesicles and AVG
Embryos at stage HH18 (65 h of incubation) were obtained and
the otic vesicles were dissected from the surrounding mesenchymal
tissue with sharpened tungsten needles, they were transferred into
four-well culture-plates (Nunc, Roskilde, Denmark) and then
incubated at 37uC in a water-saturated atmosphere containing 5%
CO2, as described previously [7]. The standard culture medium
consisted of M199 medium with Earle’s salts (Sigma-Aldrich, Saint
Louis, MO) supplemented with 2 mM glutamine (Gibco, Paisley,
UK) and antibiotics [50 IU/ml penicillin (Ern, Barcelona, Spain)
and 50 mg/ml streptomycin (CEPA, Madrid, Spain)]. AVG were
obtained from stage HH19
+ chicken embryos dissected out
aseptically and plated onto glass coverslips that had been
previously coated with poly-D-lysine and fibronectin [5]. The
AVG was cultured in 0.25 ml F12/Dulbecco’s modified Eagle
medium (Gibco) containing 100 mg/ml transferrin, 16 mg/ml
putrescine, 6ng/ml progesterone, 5.2 ng/ml sodium selenite (all
from Sigma), and antibiotics as above.
Explanted otic vesicles were treated with IGF-I (10 nM,
Recombinant IGF-I Roche Molecular Biochemicals, Basel,
Switzerland), various concentrations of Sorabenib (BAY 43-9006
1, 5 and 10 mM; Bayer HealthCare Pharmaceuticals, West Haven,
CT, USA), the MEK inhibitor U0126 (50 mM; Promega,
Madison, WI), the C-RAF inhibitor GW5074 (1 mM; Sigma-
Aldrich, Saint Louis, MO) the PI3K inhibitor LY294002 (25 mM;
Cell Signaling Boston, MA) or a pan-caspase inhibitor Boc-D-
FMK (100 mM; Calbiochem La Jolla, CA) for the times indicated
in the text. The solvent used (DMSO) had no detectable effect on
cultured otic vesicles when used at a final concentration of 0.01%
for LY294002, Boc-D-FMK and Sorafenib cultures, and 0.2% for
U0126 cultures. Otic vesicles cultured in medium without
additives were used as controls (0S). For immunostaining and
TUNEL labeling otic vesicles were fixed for 2 h in 4% (w/v)
paraformaldehyde (Merck, Darmstadt, Germany) at 4uC. When
indicated, the otic vesicle and AVG areas were measured using
Image Analysis Software (Olympus, Tokyo, Japan). At least five
explants per condition were assayed from 2–6 independent
experiments and the statistical significance was estimated using
the Student’s t-test.
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Inner ears from chicken embryos were pooled to obtain RNA at
different stages: HH18 (n=40), HH22 (n=25), HH24 (n=20) and
HH27 (n=10). Three independent RNA pools from each stage
were isolated with Trizol (Invitrogen) following the manufacturer’s
instructions, and the integrity and concentration of the RNA was
assessed with an Agilent Bioanalyzer 2100 (Agilent Technologies).
From this RNA, cDNA was generated by reverse transcription
(High Capacity cDNA Reverse Transcription Kit: Applied
Biosystems). Real-Time PCR of each pool was performed in
triplicate using specific oligonucletides from ‘‘Quantitec Primer
Assays’’ for chicken B-Raf and C-Raf (Gg_BRAF_1_SG
(QT01141413), Gg_RAF1_1_SG (QT00599123); Geneglobe, Qia-
gen) and using SYBR Green as the detection system. PCR was
performed on an Applied Biosystems 7900HT Real-Time PCR
System using eukaryotic 18S rRNA as the endogenous housekeep-
ing gene (Hs99999901_s1, TaqMan, Applied Biosystems). The
estimated gene expression was calculated as 2
2DDCt and statistical
significance was estimated using the Student’s t-test.
Western blotting
Otic vesicles (HH18) were isolated and cultured, 30 otic vesicles
from each condition were homogenized in ice cold Laemmli buffer
with 50 mM dithiotreitol (DTT), Phosphatase Inhibitor Cocktail 2
and Protease Inhibitor Cocktail (both 1:100, from Sigma-Aldrich).
The homogenized samples were heated at 95uC for 5 min and
frozen immediately. Gels were loaded with solutions containing
equal amounts of proteins and the otic vesicle protein extracts were
resolved by SDS-PAGE on 8% or 12% polyacrylamide gels. The
proteins were transferred to nitrocellulose membranes and after
incubation with blocking solution (5% non-fat dry milk in TRIS-
buffered saline with 0.1% Tween-20: TBS-T), the membranes were
probed overnight at 4uC with the appropriate specific primary
antibodies to analyze the RAF kinases, pERK/ERK or pAkt/Akt
[14] (See Supplementary material Table S1). All antibodies were
diluted in blocking solution except anti-phospho-Akt antibody,
which was diluted in TBS-T and 5% bovine serum albumin (BSA:
Sigma-Aldrich, Saint Louis, MO). The membranes were subse-
quently washed and then incubated with the appropriate peroxi-
dase-conjugated secondary antibody (1:3000) for 1 h at RT.
Antibody binding was visualized by chemiluminiscence (GE
Healthcare, Buckinghamshire, UK) and exposed to X-ray film
(Konica Minolta, Wayne, NJ). The films were scanned and the
bands quantified by densitometry with Image J software (Wayne
Rasband, National Institutes of Health, USA). At least three
independent experiments were performed per condition and the
statistical significance was estimated using the Student’s t-test.
Inmunohistochemistry
The sources, dilution, and cell specificities of the antibodies used
for immunofluorescent staining are shown in Supplementary
material Table 1. Samples were washed and permeabilized in 1%
PBS/Triton-X-100 (PBS-T), and they were exposed to the
primary antibodies overnight at 4uC. Non-specific binding sites
were blocked for 1 h in PBS-T, 3% (wt/vol) BSA (Sigma-Aldrich)
and 5% (vol/vol) normal goat serum.
For single immunostaining, sections were incubated for 2 h in a
biotinylated anti-rabbit secondary antibody (1:100, biotin-conju-
gated anti-rabbit, Chemicon), processed with ExtrAvidin-peroxi-
dase conjugate solution (1:200, Sigma). Finally, antibody binding
was visualized using DAB as the chromogen and the sections
mounted in Mowiol for observation under a Nikon 90i microscope.
For immunofluorescent staining of frozen sections, the primary
antibodies were used as described above and the secondary
antibodies were incubated for 2 h at room temperature. For dual-
fluorescence immunolabeling, otic vesicles were incubated with
Alexa Fluor 488 goat anti-mouse (1:200), Alexa Fluor 647 goat
anti-rabbit and/or Alexa Fluor 546 goat anti-rabbit secondary
antibodies (1:200; all from Molecular Probes, Eugene, OR).
TxRed-conjugated phalloidin was used to identify the apical actin-
containing structures of hair cells. Control experiments omitting
the primary antibody were carried out to confirm that the staining
patterns were specific for antigen recognition and additionally
frozen sections from wild type or B-Raf
2/2 null embryos were
included as negative controls (data not shown). The sections were
mounted in Prolong Gold with DAPI (Invitrogen, Carlsbad, CA)
and visualized by fluorescence (Nikon 90i, Tokyo, Japan) or
confocal microscopy (Leica TCS SP2, Wetzlar, Germany). For
whole-mount immunofluorescence, otic vesicles were incubated
with the secondary antibodies for 3 h at room temperature, the
otic vesicles were mounted in Vectashield with DAPI (Vector,
Peterborough, UK) and the fluorescence was visualized by
confocal microscopy (Leica TCS SP2, Wetzlar, Germany). At
least five to six otic vesicles/frozen sections were analyzed for each
condition from at least two independent experiments.
BrdU incorporation and immunodetection
To study cell proliferation, otic vesicles were incubated with 5-
Bromo-29-deoxyuridine (Sigma-Aldrich, Saint Louis, MO), a
thymidine analogue that is incorporated into DNA during the S
phase of the cell cycle. BrdU (10 mg/ml) was added to the culture
medium 1 h before the end of the incubation and its incorporation
was detected with a specific antibody as above, but including a
DNA denaturation step as recommended by the manufacturer
(incubation in 50% (v/v) formamide-SSC, 40 minutes at 65uC and
in HCl 2N, 30 minutes at 37uC, with a wash for 10 minutes in
Tris 0.1M [pH 8]). At least five to six otic vesicles were assayed per
condition in three independent experiments.
In situ hybridization
In situ hybridization was performed on cryostat sections (20 mM)
of specimens from HH24 embryos essentially as described
previously with only minor modifications [13]. Digoxigenin-
labeled sense and antisense RNA probes (1 mg/ml) were
hybridized overnight at 72uC and their binding was detected by
overnight incubation with an alkaline phosphatase-conjugated
anti-digoxigenin antibody (1:3500, Roche Applied Science), which
was visualised with 5-Bromo-4-chloro-3-indolyl phosphate, nitro
blue tetrazolium substrate (NTBT/BCIP, Roche Applied Science).
The chicken C-Raf gene was amplified by PCR (C-Raf forward 59-
ACCTGCACGTTCAAGAGACC-39; C-Raf reverse 59-GCTAC-
GAGCCTCTTCATTGC-39) and subsequently ligated into a
pGEM-T plasmid (Promega) to prepare the probe. Single-
stranded sense (ApaI/T7) and antisense (PstI/Sp6) RNA probes
were prepared by in vitro transcription and no specific signal was
obtained when control sense probes were used (data not shown).
Analysis of programmed cell death
The pattern of cell death in the otic vesicle was studied by Tdt-
mediated dUTP nick-end labeling (TUNEL) of fragmented DNA
using the kit Dead-End
TM Fluorometric TUNEL System (Promega,
Madison, WI) essentially as described by the manufacturer and
adapted to whole organ labeling [14,29]. The otic vesicles were
mounted with Vectashield with DAPI (Vector) and visualized on a
confocal microscope (Leica, TCS SP2). TUNEL-positive cells
were counted using Image Analysis Software (Olympus, Tokyo,
Japan) attributing a value of 1 to the control condition (no
addition, 0S). At least five otic vesicles were assayed per condition
RAF in Inner Ear Neurogenesis
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mean 6 SEM and the statistical significance was estimated with
the Student’s t-test.
Results
RAF kinases are expressed during early inner ear
development
The expression of chicken B-Raf and C-Raf at selected stages of
otic development was studied by quantitative RT-PCR (Figure 1 A
and B). The expression of transcripts encoding these RAF isoforms
was comparable from HH18 to HH24, although the RNA
transcripts for both these RAF kinases were strongly downregulated
at stage HH27. Moreover, B-RAF and C-RAF proteins were both
present in inner ear extracts from stage HH18 embryos, the stage at
which otic vesicles can be explanted and cultured ex vivo (Figure 1
C). Indeed, there was a significant amount of phosphorylated ERK,
a read out of RAF activity [30]. The presence of RAF kinases was
further confirmed by immunohistochemistry for B-RAF and in situ
hybridization for C-Raf (Figure 1 D) and the AVG was strongly
stained for both RAF kinases. In addition, B-RAF expression was
also evident in the otic epithelium (arrowheads in Figure 1 D).
Spatiotemporal expression of B-RAF during inner ear
development
In inner ear sections from HH24, HH27 and HH34 embryos,
the distribution of B-RAF was determined by immunohistochem-
istry (Figure 2). The different cell types labeled were identified by
Figure 1. Expression of the B-RAF and C-RAF kinases during otic development. (A) Schematic drawings showing the development of the
chicken inner ear at Hamburger and Hamilton stages HH18, HH24 and HH27. (B) Expression of inner ear B-Raf and C-Raf mRNA analyzed by qRT-PCR
at different stages using Eukaryotic 18S rRNA as the endogenous housekeeping control gene. Gene expression was calculated as 2
2DDCt and
normalized to the levels at HH18. The results are expressed as the mean 6 SEM of at least three independent experiments performed in triplicate.
Statistical significance was estimated with the Student’s t-test: ***P,0.005 versus HH18,
##P,0.01 versus HH24 and
###P,0.005 versus HH24. (C)
HH18 otic vesicle lysates analyzed in western blots to determine the levels of B-RAF, C-RAF and phosphorylated ERK (pERK). ß-Tubulin (ß-Tub) was
used as a loading control. A representative blot of three independent experiments is shown and the average densitometric measurements of the B-
RAF and C-RAF bands are plotted as bars. The results are given as the mean 6 SEM of three independent experiments. (D) Immunofluorescence of B-
RAF and in situ hybridization of C-Raf at HH22 and HH24, respectively showing their location in the otic epithelium and acoustic-vestibular ganglion
(arrowheads). Abbreviations: bp, basilar papilla; ed, endolymphatic duct; es, endolymphatic sac; lc, lateral crista; ml, macula lagena; ms, macula
sacculi; mu, macula utriculi; pc, posterior crista; sc, superior crista; ssc, superior semicircular canal. Orientation: C, caudal; D, dorsal; M, medial; R,
rostral.
doi:10.1371/journal.pone.0014435.g001
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PLoS ONE | www.plosone.org 4 December 2010 | Volume 5 | Issue 12 | e14435Figure 2. Spatiotemporal expression of B-RAF in the developing inner ear. a–h) At stage HH24, B-RAF (green throughout the figure) is
abundantly expressed in the macula sacculi (ms) and in the acoustic-vestibular ganglion (avg), which is labelled red due to the expression of the
axonal marker 3A10 (a–d). B-RAF is expressed strongly in the basilar papilla (bp, e, arrow). B-RAF and SOX2 (red), a transcription factor essential for
the self-renewal of undifferentiated otic progenitors, are expressed in non-overlapping regions of the avg (e–h). i–p) At HH27, B-RAF is expressed
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PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e14435staining for the neurofilament-related 3A10 protein [6] and
SOX2, a transcription factor associated to immature pluripotent
precursors. In mammals, SOX2 participates in the specification of
the otic prosensory domain [31,32] and the generation of cochlear
neurons [33], while it is required for hair cell survival and
regeneration in the inner ear of the zebrafish [34]. B-RAF was
expressed homogenously in the otic epithelia and in the AVG at
HH18 and HH22 (Figure 1 and data not shown), while its
expression became more restricted as development proceeded. At
HH24, B-RAF was abundantly expressed in the macula sacculi
(Figure 2 a–d) and it was also expressed in the AVG, where a
subset of neuroblasts was more strongly stained for B-RAF
(Figure 2 e–h). B-RAF and SOX2 were expressed in adjacent
regions and B-RAF expression did not appear to overlap with that
of SOX2. A similar situation was also observed in the basilar
papilla where even though both proteins appeared to overlap in
some cells, the internal cells most strongly expressed B-RAF,
whereas SOX2 expression was observed more laterally (Figure 2,
arrow in e). At HH27, B-RAF expression was restricted to the
internal layer of the otic epithelia and the cells of the AVG
(Figure 2, i–p). At HH34, SOX2 was strongly expressed by
supporting cells, whereas B-RAF was expressed strongly in the
macula sacculi, limiting the region of SOX2 expression and
suggesting that B-RAF is expressed by hair cells (Figure 2, q–t). To
further explore the expression of B-RAF in hair cells, we used
TxRed-phalloidin to label the actin in the stereocilia of hair cells
(u, w). B-RAF expression was observed in the cytoplasm of both
auditory and vestibular hair cells, and in AVG neurons (Figure 2,
u–w, and data not shown). Specific hair cell expression of B-RAF
was confirmed in E18.5 wild type mice, as was the specificity B-
RAF by labeling null B-Raf mouse embryos (Figure 2, x–x9:
Magarin ˜os, Rapp and Varela-Nieto, manuscript in preparation).
The activity of RAF kinases is required for the
proliferation and survival of otic neuroepithelial cells
The RAF-MEK-ERK phosphorylation cascade can be specifically
inhibited by Sorafenib, an inhibitor of RAF kinase activity developed
to treat B-RAF-associated cancer [16]. Otic vesicles were explanted
and cultured ex vivo in the presence of Sorafenib to further
understand the roleofRAFactivationinearlyinner ear development.
This compound totally abolished ERK phosphorylation, both the
basal phosphorylation and that induced by IGF-I (Figure 3 A, left
panels). The specificity of Sorafenib to the RAF-MEK-ERK cascade
was witnessed by its failure to effect Akt phosphorylation, both basal
and IGF-I induced (right panels). Further insight into the actions of
Sorafenib wasobtainedbystudyingitseffectsoncellproliferationand
apoptosis in organotypic cultures of explanted HH18 otic vesicles.
When cultured otic vesicles were exposed to Sorafenib, cell
proliferation was reduced and apoptosis was induced in a dose-
dependent manner (Figure 3 B). The number of apoptotic TUNEL
positive cells found in the control otic vesicles (0S) was 2.5-fold higher
than that found when IGF-I was added to the medium (Figure 3 C:
[14]). However, the addition of increasing concentrations of
Sorafenib (1, 5 and 10 mM) significantly increased the number of
apoptotic cells by 1.8-,4- and 4.6-fold, respectively (Figure 3 C and B,
compare a with j and m). At the highest concentration of Sorafenib
tested (10 mM), most cells in the otocyst were TUNEL positive
(Figure 3 B, m). It is worth noting, that Sorafenib induced less
p r o g r a m m e dc e l ld e a t hi nt h eA V Gt h a ni nt h eo t i cv e s i c l e
epithelium, even though the size of the AVG decreased dramatically
(Figure 3 B, arrow in j). The cell death was caspase-dependent as it
was blocked by the pan-caspase inhibitor BOC (Figure 3 D, upper
panels, a-c, and compare b with c). Apoptosis was further studied by
combining TUNEL staining with the immunodetection of active
caspase-3 (Figure 3 D, lower panels, a–h). The Sorafenib-treated otic
vesicles showed areas of apoptotic cell death where TUNEL-labeled
apoptotic nuclei were surrounded by cytoplasm containing active
caspase-3 (Figure 3 D, lower panels, e–h).
As RAF activation leads to cell proliferation, we assessed
bromodeoxyuridine (BrdU) uptake in cultured otic vesicles to
measure the rate of proliferation. IGF-I promoted otic prolifer-
ation when compared with control cultures (Figure 3 B, compare b
and e), while Sorafenib impaired BrdU incorporation in a dose
dependent manner. As a consequence, the size of Sorafenib-
treated otic vesicles was severely reduced (Figure 3 B, b, h, k, n).
AVG size was also reduced, even though cell proliferation at the
AVG was not strongly affected by Sorafenib (Figure 3 B, arrow in
k), suggesting that neuronal cells that escaped from the RAF
blockage are resistant to Sorafenib, possibly because RAF kinase
activity is no longer required.
To confirm that the effects observed were a consequence of the
inhibition of the RAF-MEK-ERK cascade a MEK inhibitor [35],
U0126, was used (Figure 3 E). The effects of blocking RAF catalytic
activity with Sorafenib were emulated by U0126, which abolished
ERK phosphorylation (Figure 3 E), reduced cell proliferation (data
not shown) and increased apoptosis (Figure 3 E, upper panels,
compare a with b). In contrasts, treatment with the C-RAF highly
specific inhibitor GW5074 [36] showed reduced AVG size,
undifferentiated-rounded shape OV with reduced size and
increased TUNEL positive cells (Figure 3 E, upper panels, compare
c with a), but not evident changes in cell proliferation (Figure 3 E,
lower panels, compare c with a). GW5074-treatment slightly
reduced BrdU incorporation when compared to the 0S condition,
whereas Sorafenib showed a more dramatic reduction on BrdU
levels (lower panels in Figure 3 E, compare c with b). Furthermore,
treatment with GW5074 increased ERK phosphorylation (Figure 3
E), suggesting that actions of C-RAF on apoptosis are, at least in
part, independent of the activation of MEK and ERK.
These results show that inhibition of the RAF-MEK-ERK
cascade caused a reduction in the rate of cell proliferation and an
increase in the number of caspase-dependent apoptotic cells,
without affecting Akt activity, thereby leading to a decrease in the
number of neural progenitor cells.
The activity of RAF kinases is required for otic
neurogenesis
To further explore the regulation by IGF-I and the role of the
RAF-MEK-ERK cascade in otic neurogenesis, the expression of
the neuroblast markers Islet-1 and TuJ1 was analyzed in cultured
otic vesicles treated with Sorafenib in the presence or absence of
strongly in the internal cell layers of the basilar papilla (bp, i–l), whereas SOX2 is present in more external cell layers (m–p). q–w) At HH34, SOX2 is
expressed in supporting cells of the ms whereas B-RAF labels the hair cells (hc: q–t). TxRed-phalloidin staining (red) labels actin in the hc stereocilia of
the macula utriculi (mu), and B-RAF is evident in the cytoplasm (u–w). B-RAF is also expressed in the outer (OHC) and inner hair cells (IHC) of E18.5
mouse embryos (x). x9 shows a higher magnification of the sensory region in x. Schematic drawings of HH24 and HH27 inner ears are shown. The
boxed areas show higher magnifications of the selected regions. Abbreviations: avg, acoustic-vestibular ganglion; bp, basilar papilla; ed,
endolymphatic duct; es, endolymphatic sac; hc, hair cells; IHC, inner hair cells; OHC, outer hair cells; lc, lateral crista; ml, macula lagena; ms, macula
sacculi; mu, macula utriculi; sc, superior crista; ssc, superior semicircular canal; vp, vertical canal pouch. Orientation: D, dorsal; M, medial; R, rostral.
Scale bars: 100 mm.
doi:10.1371/journal.pone.0014435.g002
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PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e14435Figure 3. Selective inhibition of the RAF-MEK-ERK cascade blocks proliferation and promotes apoptosis. (A) Sorafenib inhibits the
RAF-MEK-ERK pathway. Otic vesicles were explanted from stage HH18 chicken embryos and incubated for 24 h in serum-free medium (0S). The
explants were then incubated for 1 h in serum-free medium without additives (0S), with IGF-I (10 nM), Sorafenib (Sor; 5 mM) or a combination of both
IGF-I and Sorafenib. Otic vesicles were lysed and the levels of phosphorylated and unphosphorylated ERK and Akt kinases were quantified in Western
blots by densitometry, as described in Materials and Methods. Representative blots are shown in the upper row. The results are expressed relative to
the control value (0S), which was given an arbitrary value of 100, as the mean 6 SEM of three independent experiments. Statistical significance was
estimated with the Student’s t-test: ***P,0.005 versus 0S and
##P,0.01 versus IGF-I. (B) Apoptosis and proliferation in Sorafenib-treated
cultures of otic vesicles. Apoptotic cell death was visualized by TUNEL (green) in cultured otic vesicles. Proliferation was measured by the
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PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e14435IGF-I [Figure 4, A; [6]]. The expression of Islet-1 and TuJ1 was
reduced in a dose-dependent manner in the presence of Sorafenib,
indicating that inactivation of the RAF kinase caused a loss of
neuroblasts (Figure 4 A, compare a with d, e, f). Indeed, in otocysts
exposed to Sorafenib, and hence with impaired RAF catalytic
activity, there was a dose-dependent 20 and 40% reduction in the
otic vesicle epithelia and AVG size, respectively (Figure 4 A) when
compared to otocysts cultured under control conditions (Figure 4
B). The impact of RAF inactivation on the proliferation of otic
precursors was further confirmed by studying the number of cells
in mitosis and the incorporation of BrdU (Figure 5 A, C).
IGF-I promoted cell proliferation in the AVG neuroblast
population, as witnessed by the increased number of Islet-1 positive
cells and the 160% increase of the AVG area (Figure 4 A, compare a
with b; Figure 4 B, bars on the right). TuJ1 labels neuroblasts at a
more mature stage [4] and hence, TuJ1 positive cells are diminished
or unaffected by the addition of IGF-I (Figure 4 A, compare a with b
and c). IGF-I also promoted cell proliferation in the otic epithelium
(Figure 5 A, compare b with e). In the presence of IGF-I, the number
of Islet-1 positive cells and mitosis increased in Sorafenib-treated otic
vesicles (Figure 4 A, compare c with f), while apoptosis was reduced
(Figure 5 A–C), leading to a small but significant recovery of the OV
and AVG (Figure 4 B). Because Sorafenib completely blocks IGF-I
activation of the RAF-MEK-ERK pathway (Figure 3), these results
s u g g e s tt h a tt h er e s c u eo ft h en e u roblast population by IGF-I is
mediated by an alternative pathway.
IGF-I-induction of the PI3K/Akt kinase pathway rescues
otic progenitors from apoptosis
IGF-I activates the Akt pathway even in the presence of
Sorafenib and the total inactivation of the RAF-MEK-ERK
cascade (Figure 3). To further define the roles of the RAF-MEK-
ERK and PI3K/Akt kinase pathways in otic neurogenesis, we
studied the proliferation and apoptosis of explanted otic vesicles
treated with combinations of RAF and Akt inhibitors in culture.
Cell death was studied by detecting the TUNEL positive cells
(TUNEL) and cell proliferation was detected by following the
nuclei labeled with phospho-histone-3 (PH3), which identifies cells
in the M phase of the cell cycle (Figure 5 A), or by BrdU
incorporation (Figure 5 C).
LY294002 is a well-characterized inhibitor of the PI3K/Akt
kinase pathway that specifically impairs Akt phosphorylation [37].
Inhibition of the PI3K/Akt kinase pathway increased the number
of apoptotic cells (5.5-fold) and reduced the amount of cells
expressing the mitotic marker PH3 (0.7-fold: Figure 5 A, m–o, and
bars in B and C). The presence of IGF-I partially impaired the
effects of LY294002 as the number of proliferating cells in treated
otic vesicles was similar to that of the controls (Figure 5 A, p–r, and
bars in B and C). In combination, Sorafenib and LY294002
completely abolished the effects of IGF-I on proliferation and
apoptosis (Figure 5 A, s–u). TUNEL staining was stronger in
vesicles exposed to Sorafenib and LY294002 than in those treated
with Sorafenib alone (1.3-fold) or those exposed to Sorafenib and
IGF-I (2.0-fold: Figure 5 B). The rate of proliferation was also
reduced 3-fold in the presence of Sorafenib plus LY294002 when
compared to Sorafenib alone, and 12-fold when compared to
Sorafenib plus IGF-I (Figure 5 C). These results indicate that the
protective effects of IGF-I on survival when the RAF-MEK-ERK
cascade is inhibited are mediated by the induction of the PI3K/
Akt kinase pathway. In the presence of IGF-I, Sorafenib did not
completely abolish mitosis (Figure 5 C, quantification of PH3
positive cells) but it did abolish the incorporation of BrdU (Figure 5
C, lower panels), suggesting that IGF-I can partially overcome the
effects of RAF inhibition. These data possibly reflect the capacity
of IGF-I to sustain progenitors that are already in the M-phase of
the cell cycle but not to promote cell cycle entry.
RAF activity is required for neuronal progenitor cell
differentiation and the outgrowth of processes from
sensory otic neurons
B-RAF has previously been reported to play a role in sensory
axon and dendrite growth. Figure 6 shows B-RAF and C-RAF
expression in explanted AVG cultured in serum-free medium. B-
RAF was highly expressed in the cytoplasm and in the neural
processes (Figure 6, a–d), whereas C-RAF showed a more
restricted cytoplasmic expression (Figure 6, e–h, arrowheads). To
study the role of RAF kinases in neural process outgrowth we
examined the differentiation state of AVG cultured explants.
Postmitotic otic neurons were identified by labeling with the
nuclear cyclin-dependent kinase inhibitor p27
kip1 [13] and with
TuJ1, a neural tubulin that is found in processes (Figure 7 A).
AVG neurons that have exited the cell cycle and that are located
more distally with respect to the neurogenic zone of the otic vesicle
epithelium expressed p27
kip1 (Figure 7 A, a), and their TuJ1
staining indicated that they had begun to extend axons towards
the otic vesicle (Figure 7 A, c, e, g). Sorafenib treatment of cultured
otic vesicles reduced the number of neuroblasts and mature
neurons (Figure 7 A, compare a and b) and more interestingly,
these mature neurons did not develop axons since their TuJ1
expression remained surrounding the cytoplasm (Figure 7 A, d, f,
h). These results suggested that RAF-MEK-ERK signaling is
necessary to initiate axonal growth.
To determine whether RAF activity is required for axonal
growth once differentiation has been initiated, axonal growth was
incorporation of BrdU (red) over 1 h. Otic vesicles were isolated from HH18 chicken embryos, made quiescent and cultured for 24 h in serum-free
culture medium without additives (0S), with IGF-I (10 nM), Sorafenib (Sor; 1, 5 or 10 mM) or a combination of both IGF-I and Sorafenib. Scale bars,
150 mm. (C) Cell death quantification of B. The TUNEL positive nuclei were quantified relative to the 0S condition, which was given an arbitrary
value of 1. The bars show the mean 6 SEM of at least five otic vesicles from any of the conditions shown in B. Statistical significance was estimated
with the Student’s t-test: *P,0.05 versus control, ***P,0.005 versus control,
###P,0.005 versus Sorafenib 10 mM. (D) Sorafenib increases cell
death through a caspase-dependent mechanism. Otic vesicles were isolated from HH18 chicken embryos and cultured for 24 h in serum-free
culture medium without stimuli (0S; a upper panel), or cultured in the presence of Sorafenib 5 mM (Sor; b upper panel) or in combination with the
pan-caspase inhibitor Boc-D-FMK 50 mM (Sor+BOC; c upper panel) and cell death was visualized using the TUNEL technique. Lower panel shows
apoptotic cell death visualized by TUNEL staining (green) and immunostaining for activated-caspase-3 (red) of otic vesicles cultured in free serum (0S,
a–d) or in the presence of Sorafenib 5 mM (e–h). Boxed areas in a and e are shown at a higher magnification to show the TUNEL-positive nuclei (b,f
and merge) surrounded by activated caspase-3 (c,g and merge). Scale bar, 150 mm (a,e); 20 mm (b–d and f–h). (E) Treatment of cultured otic
vesicles with the MEK inhibitor U0126 and with the C-RAF inhibitor GW5074. A representative blot of the effects of U0126 (50 mM) and
GW5074 (1 mM) on ERK phosphorylation is shown. Apoptosis in cultured otic vesicles was visualized with TUNEL (upper panels, a–c). Proliferation was
measured by the incorporation of BrdU (red) over 1 h in otocysts cultured with no additives (0S), with Sorafenib (5 mM) or with GW5074 (1 mM) (lower
panels, a–c). Scale bar: 150 mm. Compiled projections of confocal microscopy images from otic vesicles are shown. A, anterior; D, dorsal.
Abbreviations: AVG, acoustic-vestibular ganglion; OV, otic vesicle. The images shown are representative of at least three independent experiments,
using five to six otic vesicles per condition.
doi:10.1371/journal.pone.0014435.g003
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axonal glycoprotein G4 [6]. Otic vesicles were cultured for 24 h to
allow AVG formation, and the elongation of the processes was
allowed to continue for 7 h in the presence (0S- Sorafenib) or
absence of Sorafenib (0S-0S: Figure 7, B). After 24 h, mature otic
neurons have already started to extend axons to innervate the
dorsal (vestibular) and ventral (auditory) sensory epithelia (Figure 7
B, c and e). However, subsequent exposure to Sorafenib impaired
this process and the axons remained shorter than those of controls
(Figure 7 B, compare white bar in c with that in d), both in the otic
vesicle and AVG areas (Figure 7 B, compare a and e with b and f).
Similar experiments were then performed on isolated explanted
AVG to further study the role of RAF-MEK-ERK signaling in otic
neuronal differentiation. Again, exposure to Sorafenib (2.5 mM)
caused a dramatic reduction in the number and length of processes
(Figure 7 C), despite affecting the size of the AVG. When the areas
of the AVG with neuronal soma alone or plus processes were
quantified it was confirmed that RAF activity is required for otic
neuron maturation and the outgrowth of processes.
Discussion
Inner ear organogenesis requires strict spatial and temporal
regulation of cellular proliferation, death and differentiation to
generate the appropriate number of different cell types and their
interconnections [2]. IGF-I drives cell proliferation and the
Figure 4. Inhibition of the RAF-MEK-ERK cascade impairs AVG formation. (A) Otic vesicles were isolated from HH18 chicken embryos and
incubated for 24 h in serum-free culture medium without additives (0S), with IGF-I (10 nM), Sorafenib, (Sor;1, 5 or 10 mM) or a combination of Sor
(10 mM) and IGF-I. Whole otic vesicles were then immunostained for the ganglion neuroblast nuclei marker Islet-1 (green) and for the marker of neural
processes, TuJ1 (red). Fluorescence images were obtained from the compiled projections of confocal images of otic vesicles. Representative images
of at least five to six otic vesicles per condition and from at least three independent experiments are shown. Orientation: A, anterior; D, dorsal. Scale
bar: 150 mm. (B) The otic vesicles (OV) and the acoustic-vestibular ganglia (AVG) areas were measured with Image Analysis Software (Olympus, Tokyo,
Japan). The data are expressed as the mean 6 SEM relative to the control value (0S) and they were compiled from the analysis of at least five to six





RAF in Inner Ear Neurogenesis
PLoS ONE | www.plosone.org 9 December 2010 | Volume 5 | Issue 12 | e14435Figure 5. IGF-I partially rescues the effects of inhibiting RAF activity through the PI3K/Akt kinase pathway. (A) Apoptotic cell death
was visualized by TUNEL (green) in cultured otic vesicles and proliferation was detected with the mitosis marker Phospho-Histone 3 (PH3, red). Otic
vesicles were isolated from HH18 chicken embryos and cultured for 24 h in serum-free medium without additives (0S, a–c), with IGF-I (10 nM, d–f),
Sorafenib, Sor, (5 mM, g–i), LY294002 (50 mM, m–o), a combination of IGF-I and Sor (j–l), IGF-I and LY294002 (p–r) or IGF-I, Sor and LY294002 (s–u).
(B) TUNEL positive or (C) proliferative PH3-labeled cells were quantified as described in at least 5 otic vesicles per condition. The results are shown as
the mean 6 SEM relative to the 0S condition. Statistical significance was estimated with the Student’s t-test: *P,0.05, ***P,0.005 versus 0S;
#P,0.05
and
###P,0.005 versus the indicated inhibitors; ‘P,0.05, ‘‘‘P,0.005 versus Sorafenib +IGF-I. Lower panels in C show BrdU (green) incorporation
into cultured otic vesicles incubated for 24 h in the following conditions: 0S, with Sor (5 mM), or a combination of Sor and IGF-I (10 nM). Compiled
projections of confocal images from otic vesicles are shown, and are representative of at least five to six otic vesicles per condition from three
different experiments. Scale bar, 150 mm.
doi:10.1371/journal.pone.0014435.g005
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differentiation in the time window between neuronal cell fate
specification and neurotrophin dependence [4]. RAF proteins are
serine/threonine kinases that regulate the RAF-MEK-ERK
signaling pathway involved in the transduction of extracellular
stimuli into cellular responses [16]. Three RAF kinase isoforms
exist in mammals, A-, B- and C-RAF, whose activity is exquisitely
regulated at the post-transcriptional level by a number of different
mechanisms [38]. C-RAF activation is regulated by IGF-I and it is
essential for cell proliferation in the otic vesicle [15]. However, no
studies have been conducted on B-RAF even though this isoform is
more active as a protein kinase and more abundantly expressed in
the nervous system, where it is fundamental for axonal and
dendrite growth [25,27,39,40].
Here we show that B-RAF and C-RAF transcripts are expressed
during inner ear development in a specific spatiotemporal pattern
and that B-RAF is expressed specifically in neurosensorial
components of the inner ear at later stages of development.
RAF transcripts are translated into proteins that phosphorylate
ERK, and RAF activity is regulated in the inner ear by IGF-I.
Such RAF-MEK-ERK signaling is required for neuroepithelial
cell proliferation and survival in this structure, although IGF-I can
restore cell survival by activating the PI3K/Akt kinase pathway
when RAF-MEK-ERK is inhibited by Sorafenib. However, IGF-I
it is not able to restore cell proliferation in these conditions.
Finally, we demonstrate that RAF kinase activity is required for
neuronal progenitor cell differentiation and for the outgrowth of
sensory otic neuron processes.
B-RAF and C-RAF are expressed in a similar temporal pattern
from HH18 to HH27, when the striking reduction in both
transcripts suggests that the transcription of both RAF isoforms is
developmentally regulated. Up to stage HH24 these kinases are
expressed homogeneously in the otic epithelia and AVG, and
during these stages RAF kinases support the basic cellular
programmes of otic progenitors. As development proceeds, the
activity of RAF kinases may be more directly related to
differentiation and post-differentiation events, and accordingly
they become more spatially restricted. At HH27 when auditory
and vestibular hair cells have just differentiated, both RAF kinases
are down-regulated and the strongest B-RAF expression is
associated to sensory hair and neuronal cells. Indeed, RAF kinases
participate in late differentiation processes of other cell types such
as T-cells [41] and sensory cells [42], as well as in post-
differentiation events, such as cortical neuron migration [20] or
the modulation of synaptic plasticity [43].
Due to the established role of RAF kinases in cancer, the search
for inhibitors of RAF-MEK-ERK signaling has been intense [16].
Sorafenib 43-9006 is a potent small-molecule that inhibits RAF
kinases, and its use has been approved for renal carcinoma
therapy, as well as in clinical trials for melanoma and thyroid
cancer [44]. Sorafenib was primarily identified as a C-RAF
inhibitor but upon further characterization, it was shown to inhibit
B-RAF and other kinases involved in angiogenesis [24]. We have
used Sorafenib to study the influence of RAF kinases on otic
progenitors and their regulation by IGF-I. Our results show that
Sorafenib effectively inhibits basal and IGF-I induced ERK
phosphorylation, without affecting Akt phosphorylation. Inhibition
of RAF catalytic activity by Sorafenib also caused an increase in
caspase-dependent apoptosis. Interestingly, in some melanoma cell
lines this is not the case and Sorafenib-dependent apoptosis is
caspase independent [45]. RAF activation of mitochondrial targets
such as BAD [21,46], ASK-1 [47], and MST-2 [48] has an anti-
apoptotic effect and therefore, RAF inactivation can provoke cell
death. RAF inactivation also annuls the activity of the MEK-ERK
module, which along with the lack of activation of cell cycle
proteins and transcription factors, such as retinoblastoma [49],
Cdc25 [50] or AP1 [51,52], may also cause apoptosis of
proliferating cells. MEK inhibition by U0126 [35] and C-RAF
inhibition by GW5074 [36] also caused apoptosis but presented
different traits. The MEK inhibitor completely abolished ERK
phosporylation and, in contrast, GW5074 induced it. Paradoxical
actions of C-RAF inhibitors have been reported in other neuronal
contexts [53,54] and elimination of C-RAF activity by either
knocking it out or siRNA targeting did not altered ERK
phosphorylation [55,56]. Therefore, RAF quinases inactivation
could promote apoptosis of otic progenitor cells by both ERK
dependent and independent mechanisms, as reported in other cell
types [57].
Figure 6. RAF proteins show different subcellular distribution in the acoustic- vestibular ganglion. AVG explants were obtained from
stage HH19 chicken embryos and cultured in serum-free medium for 20 h with no additives (0S). (a–d) Whole AVG explants were immunostained for
B-RAF (green) and Islet-1 (red) or (e–h) for C-RAF (red) and G4 (green), The cytoplasmatic distribution of C-RAF is shown (arrowheads). Fluorescence
images were obtained from compiled projections of confocal images of AVG. Scale bar, 350 mm (a, e); 75 mm (b–d, f–h).
doi:10.1371/journal.pone.0014435.g006
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PLoS ONE | www.plosone.org 11 December 2010 | Volume 5 | Issue 12 | e14435Figure 7. RAF kinase activity is required for the correct outgrowth of sensory otic neuron processes. (A) Otic vesicles were isolated from
HH18 chicken embryos and incubated for 24 h either in serum-free medium without additives (0S, a,c,e,g) or in the presence of Sorafenib (2.5 mM)
(b,d,f,h). Immunohistochemistry of whole otic vesicles was carried out by double-staining for the nuclear cyclin-dependent kinase inhibitor p27
kip1
(green) and for the marker of neural processes, TuJ1 (red). The boxed areas in panels e and f, correspond to the enlarged images in panels g and h
respectively. Scale bar: 75 mm. (B) Otic vesicles were isolated from HH18 chicken embryos and incubated for 24 h in serum-free medium as in the 0S
condition in A, and they were then incubated for a further 7 h without additives (0S-0S, a,c,e) or with Sorafenib (2.5 mM: 0S-Sorafenib, b,d,f). Whole
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produced a dramatic decrease in cell proliferation since the RAF-
MEK-ERK cascade plays a fundamental role in the G1/S
transition, where its signaling induces cyclin D1 and down-regulates
many other antiproliferative genes [52]. Accordingly, exposing
cultured otic vesicles toSorafenibcauseda dose-dependentdecrease
of BrdU incorporation at S phase. U0126 treatment also reduced
proliferationin the otic vesicle; however, the specificinhibition of C-
RAF with GW5074 did not show the striking reduction on
proliferation observed with the other inhibitors. In mice, of the
three RAF isoforms, C-RAF appears to be preferentially involved in
promoting survival, rather than controlling proliferation [55,58]. In
contrast, B-RAF is essential for ERK activation [25] that in turn
triggers cell proliferation [59]. These data suggest that RAF kinases
also have distinct roles during chicken inner ear development. C-
RAFwouldpreferentiallypromoteanti-apoptoticsignalingwhilstB-
RAF, through the MEK-ERK module, would modulate prolifer-
ation of neuroepithelial progenitors.
Experiments with IGF-I showed that RAF activity is essential for
the progression of cell proliferation but not for cell survival. Indeed,
IGF-I was even able to rescue otic progenitors by activating the
PI3K/Akt pathway in the presence of Sorafenib. Blockage of the
PI3K/Akt kinase pathway with LY294002 indicated that IGF-I is
dependent on Akt activation for cell survival. Therefore, IGF-I
orchestrates cell proliferation and survival in the otic vesiclethrough
distinct pathways, although cross-talk between signaling pathways
also occurs, as reported in other cell contexts [60].
The AVG is generated from a pool of neuroepithelial progenitors
that when specified in the otic vesicle epithelia, migrate from the
neurogenic zone and form the ganglia [4]. C-RAF and B-RAF are
expressed in otic neurons but they exhibit distinct subcellular
distribution, as reported in the rat brain [43]. B-RAF is abundantly
expressed in cell bodies and neuronal processes, while C-RAF
expression is more restricted to the cytoplasmic compartment.
Exposure to Sorafenib caused a dramatic decrease in the area of the
AVG, although inhibiting RAF kinase activity did not appear to
affect the population of neuronal cells in the AVG, which continued
to proliferate and exhibited little apoptosis. These data suggest that
mature neurons do not require RAF kinases for survival but that
RAF activity is essential for early neurogenesis. Accordingly,
Sorafenib caused a clear reduction of mature neurons as indicated
by the reduced levels of axonal outgrowth markers. This
observation suggested that the RAF-MEK-ERK cascade may be
involved in differentiation of neural cells in the AVG, as seen in the
differentiation of cortical and dorsal neurons [42,40]. Otic neuronal
identity and axonal growth are determined by various factors once
the cell has exited the cell cycle [4]. Axonal growth in post-mitotic
p27
kip1 positive AVG neurons was almost completely inhibited in
the presence of Sorafenib, indicating that RAF kinase activation
plays a fundamental role in the late differentiation of otic neurons.
In summary, we show here that B-RAF and C-RAF are
expressed during chicken inner ear development in specific
spatiotemporal patterns, and that RAF-MEK-ERK signaling is
required for neuroepithelial cell proliferation and otic neuronal
differentiation.
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